Sopharma Jsc saw its net non-consolidated earnings for the Jan – Sept period plunge from 25.98 million leva to 15.08 million leva (7.71 mln euros). This is a decline of 41.9% on year, according to company information posted in the website of BSE-Sofia.

Profit is down, in spite of a 13% hike in revenues, from 124.25 million to 140.41 million leva (7.17 mln euros). The increase is due to rising revenues from core activity.

At the same time, the pharmaceutical company saw costs rise by 29.6% to 123.59 mln leva, compared with 95.37 mln leva.

The company's core capital rose to 219.78 mln leva (112.3 mln euros).

As at 30 September equity capital is at 132 mln leva (67.4 mln euros), allocated in 132 million shares with a par value of 1 lev each.

The company's Reserves fund is in the amount of 12.441 mln leva (6.36 mln euros).

Majority shareholder is Donev Investments Jsc, which controls a total of 25.64% of the capital as at end of September, and Telecomplect (20.42%). Individual investors hold some 2.95%.

Sopharma owns controlling stakes in 12 companies – Sopharma Trading, Balgarska Roza Sevtopolis, Pharamlogistics, Rosbalkanpharm, Eletroncommerce, Biopharma Engineering, Sopharma Zdrovit, Sopharma Poland, Sopharma USA, Mineralcommerce, Ivanchich and sons, Vitamina Jsc.

The company also holds stakes in two associated firms – Momina Krepost Jsc and Sopharma Logistics Jsc (Fintexco Jsc), and in 16 other enterprises.